I was very impressed by Missling's Jefferies presenting, lots of good stuff. Btw re Bryostatin, it shoukd be noted that Neurotrope's market cap is about $60MM, one quarter of Anavex's, and even less when you take out cash. So much for "Anavex is being manipulated". The market gives us a very healthy relative market cap given the risks and compared to some others. Will be nice when we get the kind of market recognition that Axovant has.